Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis
Top Cited Papers
- 4 February 2003
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 138 (3) , 176-186
- https://doi.org/10.7326/0003-4819-138-3-200302040-00009
Abstract
Once-in-a-lifetime screening for Barrett esophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is little evidence of its cost-effectiveness. 1] To determine the cost-effectiveness of screening high-risk groups for Barrett esophagus and providing surveillance to patients with Barrett esophagus and dysplasia or to all patients with Barrett esophagus and 2) to compare the results with the cost-effectiveness of no screening or surveillance. A decision analytic model was developed to examine no screening or surveillance and screening and surveillance for Barrett esophagus with dysplasia only or Barrett esophagus without dysplasia every 2 to 5 years. Low- or high-grade dysplasia received surveillance every 6 or 3 months, respectively. Published literature and the Health Care Financing Administration. 50-year-old white men with symptoms of GERD. 50 years of age until 80 years of age or death. Third-party payer. Incremental cost-effectiveness ratio. Screening with surveillance limited to patients with Barrett esophagus with dysplasia required $10 440 per quality-adjusted life-year (QALY) saved compared to no screening or surveillance. The incremental cost-effectiveness ratio of surveillance every 5 years in patients with Barrett esophagus without dysplasia compared to surveillance of patients with Barrett esophagus with dysplasia was $596 000 per QALY saved. The annual incidence of adenocarcinoma must exceed 1 case per 54 patient-years of follow-up (1.9%) for surveillance of Barrett esophagus without dysplasia every 5 years to yield an incremental cost-effectiveness ratio less than $50 000 per QALY saved. Screening 50-year-old men with symptoms of GERD to detect adenocarcinoma associated with Barrett esophagus is probably cost-effective. However, subsequent surveillance of patients with Barrett esophagus but no dysplasia, even at 5-year intervals, is an expensive practice.Keywords
This publication has 11 references indexed in Scilit:
- Long-Term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease: Follow-Up of a Randomized Controlled TrialSurvey of Anesthesiology, 2002
- Minimally invasive esophagectomy for Barrett’s esophagus with high-grade dysplasiaSurgery, 2000
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaNew England Journal of Medicine, 1999
- Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical dataGastroenterology, 1999
- Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinomaGut, 1998
- Esophagogastrectomy for carcinoma of the esophagus and cardia: A comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteriaThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Complications and hazards of gastrointestinal endoscopyWorld Journal of Surgery, 1989
- The Markov Process in Medical PrognosisMedical Decision Making, 1983
- Chinese Experience in the Surgical Treatment of Carcinoma of the EsophagusAnnals of Surgery, 1979
- Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy SurveyPublished by American Medical Association (AMA) ,1976